Risk prediction for clonal cytopenia: multicenter real-world evidenceZhuoer Xie, Aref Al‐Kali, Rami S. Komrokji et al.|Blood|2024Cited by 51
The Characteristics and Prognosis of Patients with Clonal Cytopenias of Undetermined Significance, Including Cancer and Therapy-Related Clonal CytopeniasZhuoer Xie, Aref Al‐Kali, Alexandra N. Smith et al.|Blood|2022Cited by 6
Characteristics and Clinical Outcome of Patients with Clonal Cytopenias of Undetermined Significance: A Large Retrospective Multi-Center International StudyZhuoer Xie, Aref Al‐Kali, Rami S. Komrokji et al.|Blood|2021Cited by 6
A blueprint for pursuing therapeutic interventions and early phase clinical trials in clonal haematopoiesisTamanna Haque, Michael R. Savona, Aditi Shastri et al.|British Journal of Haematology|2024Cited by 6
Ivosidenib leads to durable responses in IDH1 mutated clonal cytopenias of undetermined significance: A phase II decentralized clinical trialKelly L. Bolton, Eytan M. Stein, Maria Stoentcheva et al.|Blood|2025Cited by 2